Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood (2022) 140 (3): 285–289.

https://doi.org/10.1182/blood.2022015832

Published: 2022

Includes: Supplemental data

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Fecal Microbiota Transplantation As a Treatment of Severe Steroid-Resistant Acute and Chronic Graft Versus Host Disease. Spectrum of Responses and Complications

Jaroslaw Bilinski, MD PhD, Karol Lis, MD, Agnieszka Tomaszewska, MD PhD, Pawel Grzesiowski, MD PhD, Aleksandra Pechcinska, Tomasz Dzieciatkowski, Kazimierz Halaburda, MD PhD, Magdalena Tormanowska, MD PhD, Martyna Tyszka, MD, Krzysztof Mądry, MD PhD, Ewa Karakulska-Prystupiuk, MD PhD, Alicja Hoffman, Wieslaw W. Jedrzejczak, MD PhD, Grzegorz W Basak, MD PhD Professor

Blood (2019) 134 (Supplement_1): 5667.

https://doi.org/10.1182/blood-2019-127063

Published: 2019

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Blood (2019) 134 (Supplement_1): 4235.

https://doi.org/10.1182/blood-2019-129614

Published: 2019

Journal Articles

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Tycel J. Phillips, MD, Stephen D. Smith, MD, Wojciech Jurczak, Tadeusz Robak, MD PhD, Don Stevens, MD, Charles M. Farber, MD PhD, John M. Pagel, MD PhD, Kami J. Maddocks, MD, Ian W. Flinn, MD PhD, Wieslaw W. Jedrzejczak, MD PhD, Andre Goy, MD, Pier Luigi Zinzani, MD, Jan Zaucha, MD PhD, Morton Coleman, MD, Tianling Chen, MD, Sun Ku Lee, PhD, Wei Liang, PhD, Anna Seto, PharmD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 4144.

https://doi.org/10.1182/blood-2018-99-110617

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP and IEWP) of the EBMT

Rafal Machowicz, MD MSc, Felipe Suarez, MD PhD, Wieslaw W Jedrzejczak, MD PhD, Dirk-Jan Eikema, Liesbeth C de Wreede, PhD, Henric-Jan Blok, Cecilia Isaksson, MD, Hermann Einsele, MD, Xavier Poiré, MD, Manos Nikolousis, MD PhD, Jan-Erik Johansson, MD PhD, Guido Kobbe, MD, Marco Zecca, MD, Renate Arnold, MD PhD, Jose L. Diez-Martin, MD PhD, Stefan Schönland, MD, Arjan C Lankester, MD PhD, Andrew Gennery, MD, Nicolaus Kroeger, MD Prof

Blood (2016) 128 (22): 3490.

https://doi.org/10.1182/blood.V128.22.3490.3490

Published: 2016

Journal Articles

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Shaji Kumar, MD, Norbert Grzasko, MD PhD, Sosana Delimpasi, MD, Wieslaw W Jędrzejczak, MD, Sebastian Grosicki, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Andrew Spencer, Neeraj Gupta, PhD, Zhaoyang Teng, PhD, Catriona Byrne, RN, Richard Labotka, MD MS, Meletios A Dimopoulos

Blood (2016) 128 (22): 3327.

https://doi.org/10.1182/blood.V128.22.3327.3327

Published: 2016

Journal Articles

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Blood (2016) 127 (6): 713–721.

https://doi.org/10.1182/blood-2015-09-665018

Published: 2016

Includes: Supplemental data

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)

Elzbieta Patkowska, MD, Joanna Gora Tybor, MDPhD, Ewa Lech Maranda, MDPhD, Maciej Kazmierczak, MDPhD, Marta Baranska, MD PhD, Andrzej Szczepaniak, MD, Monika Paluszewska, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Renata Guzicka Kazmierczak, MD PhD, Wanda Knopinska Posluszny, MD PhD, Olga Grzybowska Izydorczyk, MD PhD, Jaroslaw Piszcz, MD PhD, Izabela Deren Wagemann, MD PhD, Krzysztof Warzocha, MD PhD

Blood (2015) 126 (23): 1321.

https://doi.org/10.1182/blood.V126.23.1321.1321

Published: 2015

Journal Articles

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2015) 126 (23): 3026.

https://doi.org/10.1182/blood.V126.23.3026.3026

Published: 2015

Journal Articles

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Blood (2015) 126 (23): 4230.

https://doi.org/10.1182/blood.V126.23.4230.4230

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT

Grzegorz W. Basak, MD, PhD, Wieslaw W. Jedrzejczak, MD, PhD, Helene Schoemans, MD, Per T. Ljungman, MD, PhD, Guido Kobbe, MD, Yves Beguin, MD, PhD, Peter Lang, MD, Karl-Walter Sykora, MD, Liane CJ te Boome, MD, Anja van Biezen, Steffie van der Werf, Mohamad Mohty, MD, PhD, Theo de Witte, MD, Judith Marsh, Peter Dreger, MD, Nicolaus Kroeger, MD, Rafael F. Duarte, MD, PhD, Tapani Ruutu, MD PhD

Blood (2013) 122 (21): 2110.

https://doi.org/10.1182/blood.V122.21.2110.2110

Published: 2013

Journal Articles

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Blood (2009) 114 (22): 788.

https://doi.org/10.1182/blood.V114.22.788.788

Published: 2009

Journal Articles

Polish Myelodysplastic Syndromes Registry- Report of 15 Months of Activity.

Blood (2009) 114 (22): 4848.

https://doi.org/10.1182/blood.V114.22.4848.4848

Published: 2009

Journal Articles

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Blood (2009) 114 (6): 1166–1173.

https://doi.org/10.1182/blood-2009-01-198093

Published: 2009

Journal Articles

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

Blood (2008) 112 (11): 4301.

https://doi.org/10.1182/blood.V112.11.4301.4301

Published: 2008

Journal Articles

A Randomized Phase 3 Study of Tipifarnib Compared to Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients 70 Years or Older.

Jean-Luc Harousseau, Giovanni Martinelli, Wieslaw W. Jedrzejczak, Joseph Brandwein, Dominique Bourdessoule, Tamas Masszi, Gert Ossenkoppele, Julia A. Alexeeva, Gernot Beutel, Youn C. Park, Peter De Porre, Angela J. Howes

Blood (2007) 110 (11): 439.

https://doi.org/10.1182/blood.V110.11.439.439

Published: 2007

NARROW

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Fecal Microbiota Transplantation As a Treatment of Severe Steroid-Resistant Acute and Chronic Graft Versus Host Disease. Spectrum of Responses and Complications

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP and IEWP) of the EBMT

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Clinical Features and Outcome of Patients with Acute Myeloid Leukaemia (AML) and Central Nervous System Involvement at the Time of Diagnosis and during the Course of AML - Retrospective, Multicentre Study of the Polish Adult Leukemia Group (PALG)

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Polish Myelodysplastic Syndromes Registry- Report of 15 Months of Activity.

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

A Randomized Phase 3 Study of Tipifarnib Compared to Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients 70 Years or Older.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only